Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
In brief
The purpose of this study is to determine, in patients undergoing carotid endarterectomy, the effect of ARC1779 Injection on the number of microembolic signals detected by transcranial Doppler immediately after surgery. This study will also evaluate the safety of ARC1779 Injection with respect to bleeding risk in patients in the peri-operative (during surgery) period.
Key facts
- Study ID
- NCT00742612
- Run by
- Archemix Corp.
- People needed
- 100
- Starts
- 2009-02-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2010-02-10
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female patients;
- >/= 18 to </= 80 years of age;
- Carotid stenosis (either symptomatic or asymptomatic);
- Planned carotid endarterectomy;
- Female patients must be non-pregnant and willing to use effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment;
- Male patients must agree to use a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment;
- All patients must be capable of understanding and complying with the protocol and must have signed the informed consent document.
You may not qualify if…
- Lack of acoustic window allowing TCD recordings;
- Unable or unwilling to consent;
- Metallic prosthetic cardiac valve;
- Recent (<4 weeks) ischemic stroke involving >1/3 of the MCA territory;
- Any history of hemorrhagic stroke;
- Thrombocytopenia;
- Coagulopathy;
- Trauma or surgery within preceding 30 days;
- History of bleeding disorder, gastrointestinal ulcers, or other medical problem associated with an increased risk of bleeding;
- Use of warfarin and any chronic antithrombotic therapy other than acetylsalicylic acid and/or dipyridamole; patients previously treated with warfarin are eligible if the drug has been discontinued and the INR prior to randomization has returned to <1.3;
- Use of clopidogrel, unless it has been discontinued at least 5 days prior to randomization;
- Fibrinolytic or GPIIb/IIIa inhibitor treatment within the preceding 24 hours.
Where it is running
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Eddy Scurlock Stroke Center - Methodist Hospital — Houston, Texas, United States
- Addenbrooke's Hospital, Department of Vascular Surgery — Cambridge, United Kingdom
- University Hospitals Coventry and Warwickshire NHS TRUST — Coventry, United Kingdom
- Leeds General Infirmary — Leeds, United Kingdom
- St. George's, University of London, Cranmer Terrace — London, United Kingdom
- University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.